Kaneka Eurogentec to build biodrug production plant in Belgium

By Gareth Macdonald contact

- Last updated on GMT

iStock/alexis84
iStock/alexis84

Related tags: Biotechnology, Bacteria

Kaneka Eurogentec has announced plans to build a biopharmaceutical manufacturing facility in Seraing, Belgium.

The facility – which will be adjacent to the contract manufacturing organisation’s (CMO) plant – will produce protein-based drugs, antibody fragments and plasmid DNA for therapeutics. The plant will house a 2,200L fermenter.

The firm – which is owned by Japanese chemical producer Kaneka – cited “current market need” as motivation for building the new plant.

Executive vice president Lieven Janssens said: “The rapid growth in cell and gene therapy products is driving the need for large batches of plasmid DNA.

He added that:  “Our existing pharma and biotech customers have already expressed the need for kilo-scale manufacturing capabilities and we have developed equipment and methods to respond to these needs with the new facility​.”

Work on the plant is due to start this year according to Kaneka Eurogentec, which said it will be equipped with a 2,200L fermenter for the production and purification of biomedicines using microbial strains.

The firm also said it plans to hire 40 additional production staff to work at the plant.

Related news

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars